Cambridge, UK, 25th October 2017 – Microbiotica, a leading player in microbiome-based therapeutics, today announces that Nigel Crockett, Head of Business Development, will participate in the Microbiome panel at the 23rd Annual International Partnering Conference, BIO-Europe®, which will be held from 6-8 November, in Berlin, Germany.
The discussion, entitled ‘Targeting the microbiome: From scientific evidence to regulatory approval‘, will take place on 6th November at 2.45 pm. The panel will discuss the therapeutic potential of this fast-growing field of research and the variety of strategies that companies have to choose from, as well as considering how companies select the best clinical and regulatory pathway for their products.
BIO-Europe® is Europe’s largest life science partnering conference; it provides a forum for companies across the biotech industry to meet and do business, through its range of workshops, exhibitions, panels and one-to-one meetings.
Microbiotica, spun-out of the Wellcome Trust Sanger Institute in 2016, was formed around ground-breaking research led by Dr Trevor Lawley and is focused on microbiome biology and its use in medicine, covering both novel bacterial therapeutics and patient diagnostics.